Bioavailability of BI 144807 Given Alone and in Combination With Ketoconazole in Healthy Male Volunteers

Phase 1CompletedNCT01707940

Boehringer Ingelheim24 enrolled

Overview

This trial investigates the influence of oral ketoconazole on the pharmacokinetics and safety of BI 144807.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Ketoconazole 400 mg / day

BI144807 oral solution, intermediate dose

BI144807 oral solution, intermediate dose

Sex: MALEMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion criteria: 1\. healthy male subjects Exclusion criteria: 1\. any relevant deviation from healthy conditions

1313.7.1 Boehringer Ingelheim Investigational Site

Biberach, Germany

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity

Time frame: 0 to 48 hours after administration

Maximum measured concentration of the analyte in plasma

Time frame: 0 to 48 hours after administration

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point

Time frame: 0 to 48 hours after administration

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.